Clinical Trial Update: Suppression Of Atrial Fibrillation With Ranolazine After Cardiac Surgery [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating ranolazine to suppress atrial fibrillation after cardiac surgery was terminated, with results posted in January 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Ranexa (ranolazine)

Snippet

Sponsor: Corewell Health East | Conditions: Heart; Dysfunction Postoperative, Cardiac Surgery | Phase 3 | Status: TERMINATED | Results posted: 2017-01-06